Intellia Therapeutics, Inc

Day range

$10.58 – $11.24

Open

$11.00

Prev close

$11.16

Volume

3.57M

Market cap

$1.56B

Shares out

140.13M

P/E

—

P/S

26.28

P/B

2.15

P/FCF

—

ROE

-55.0%

ROA

-46.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Business developmentsSep 8, 2026

  The U.S. Food and Drug Administration ("FDA") has accepted the Biologics License Application ("BLA") for lonvoguran ziclumeran ("lonvo-z") and granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of March 10, 2027. Additionally, FDA has advised the Company that it is not currently planning to hold an advisory committee to discuss the application.

• Debt activitySep 4, 2026

  The Credit Agreement provides the Company with a five-year senior secured credit facility of up to $400 million ... (1) $75 million drawn on the Closing Date.

• Business developmentsJun 15, 2026

  On June 13, 2026, the Company announced additional positive results from the global Phase 3 HAELO clinical trial of lonvoguran ziclumeran or 'lonvo-z' (formerly NTLA-2002) for hereditary angioedema ('HAE'). The results were presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology ('EAACI') Annual Congress 2026 in Istanbul, Türkiye, and were simultaneously published in the New England Journal of Medicine.

• Shareholder meetingsJun 10, 2026

  On June 9, 2026, Intellia Therapeutics, Inc. (the "Company") held its Annual Meeting to consider and vote on the three proposals set forth below... The stockholders of the Company elected each of Muna Bhanji, R.Ph., Brian Goff and Jesse Goodman, M.D., M.P.H., as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2029.

• Equity activityApr 30, 2026

  On April 28, 2026, Intellia Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc., related to a public offering of 16,744,187 shares of common stock at a price to the public of $10.75 per share. The Underwriters exercised a 30-day option to purchase up to an additional 2,511,628 shares in full on April 29, 2026. The Offering closed on April 30, 2026.

• CRSPCRISPR Therapeutics AG-1.20%
• BEAMBeam Therapeutics Inc. Common Stock-2.08%
• CRSPCRISPR Therapeutics AG-1.20%
• EDITEditas Medicine, Inc. Common Stock-3.61%

Days to cover

9.5

Short interest

45.11M

Avg volume

4.77M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
  positiveZacks Investment Research· Oct 20, 2026
• Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
  neutralZacks Investment Research· Oct 9, 2026
• Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
  neutralGlobeNewswire Inc.· Sep 17, 2026
• Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
  positiveGlobeNewswire Inc.· Sep 4, 2026
• Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
  positiveGlobeNewswire Inc.· Sep 4, 2026